Call to arrange a consultation
+1 416 777 0888

Warren Sprigings

Partner

Warren’s practice has focused on litigation in the pharmaceutical industry including Patented Medicines (Notice of Compliance) proceedings, patent infringement / validity proceedings, trademark actions and oppositions and damage quantifications. Warren is a registered Canadian Patent and Trademark Agent, as well as a registered U.S. Patent Agent. His experience includes drafting and prosecuting patent and trademark applications.

Education

  • B.A.SC., University of Ottawa
  • LL.B., University of Ottawa

Bar Admission

  • Ontario, 1992

Warren Sprigings

Recent Cases

Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,402,894 (saxagliptin)

Application  for leave to appeal to the Supreme Court of Canada in a patent impeachment action relating to Patent No. 2,261,630 (infliximab)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,762,013 and 2,620,380 (pirfenidone)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,937,365 (pirfenidone)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,620,380 (pirfenidone)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,631,646 (pirfenidone)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,667,654 (pirfenidone)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,709,997 (pirfenidone)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,710,014 (pirfenidone)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,710,358 (pirfenidone)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,819,967 (pirfenidone)

Interlocutory appeal in a patent impeachment action relating to Patent No. 2,261,630 (infliximab)

Action under the Trademarks Act and the Competition Act regarding Registration Nos. TMA580,557 (ENERGIZER MAX), TMA157,162 (ENERGIZER) and TMA740,338 (ENERGIZER)

Motion/Application under the new Patented Medicines (Notice of Compliance) Regulations

Interlocutory appeal in a patent impeachment action regarding Patent No. 2,261,630 (infliximab)

Appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab)

Statutory appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab)

Interlocutory appeal in a patent impeachment action regarding Patent No. 2,261,630 (infliximab)

Interlocutory appeal in a patent impeachment action regarding Patent No. 2,261,630 (infliximab)

Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,415,403 (acetaminophen)

Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,705,733 (acetaminophen)

Patent infringement case regarding Patent No. 2,407,556 (trastuzumab)

Patent impeachment case regarding Patent No. 2,540,547 (trastuzumab)

Patent impeachment case regarding Patent No. 2,329,829 (trastuzumab)

Patent impeachment case regarding Patent No. 2,376,596 (trastuzumab)

Patent impeachment case regarding Patent No. 2,596,133 (pertuzumab)

Patent infringement case regarding Patent No. 2,787,952 (bevacizumab) with counterclaim for infringement under the new Patented Medicines (Notice of Compliance) Regulations

Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,366,785 and 2,476,934 (etanercept)

Appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab)

Interlocutory appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab)

Interlocutory appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab)

Action under the Trademarks Act and the Competition Act regarding Registration Nos. TMA580,557 (ENERGIZER MAX), 157,162 (ENERGIZER) and 740,338 (ENERGIZER)

Interlocutory appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab)

Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,261,630 (Infliximab).

Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,166,483, 2,186,037, 1,338,377, 2,133762, 2,170,647, 2,290,963, 2,346,988, 2,166,794, 2,139,653, 2,180,535, 2,290,531, 2,226,184 and 2,193,994 (esomeprazole)

Trademark infringement case regarding Registration No. TMA396,079 (FREEDOMWALKER)

Trademark infringement case regarding Registration No. TMA396,079 (FREEDOMWALKER)

More people

Interested in joining the team?

We are always on the lookout for talented individuals.

View Careers